Eftilagimod alpha (LAG-3 protein) in combination with pembrolizumab in a phase-II study (TACTI-002) has been shown to achieve a response in a PD-L1 unselected metastatic non-small cell lung cancer population in the first-line setting. Here, CD274 is linked to non-small cell lung carcinoma.